Evidence map›Paper›PMID 26589198›Full record

ReviewStem cell reviews and reports2016

Erase and Rewind: Epigenetic Conversion of Cell Fate.

Georgia Pennarossa, Alessandro Zenobi, Cecilia E Gandolfi, Elena F M Manzoni, Fulvio Gandolfi, Tiziana A L Brevini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Georgia PennarossaLaboratory of Biomedical Embryology, Unistem, Università degli Studi di Milano, Via Celoria 10, 20133, Milan, Italy.
Alessandro ZenobiLaboratory of Biomedical Embryology, Unistem, Università degli Studi di Milano, Via Celoria 10, 20133, Milan, Italy.
Cecilia E GandolfiLaboratory of Biomedical Embryology, Unistem, Università degli Studi di Milano, Via Celoria 10, 20133, Milan, Italy.
Elena F M ManzoniLaboratory of Biomedical Embryology, Unistem, Università degli Studi di Milano, Via Celoria 10, 20133, Milan, Italy.
Fulvio GandolfiLaboratory of Biomedical Embryology, Unistem, Università degli Studi di Milano, Via Celoria 10, 20133, Milan, Italy.
Tiziana A L BreviniLaboratory of Biomedical Embryology, Unistem, Università degli Studi di Milano, Via Celoria 10, 20133, Milan, Italy. tiziana.brevini@unimi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential of cell therapy in regenerative medicine has greatly expanded thanks to the availability of sources of pluripotent cells. In particular, induced pluripotent stem cells (iPS) have dominated the scenario in the last years for their ability to proliferate and differentiate into specific cell types. Nevertheless, the concerns inherent to the cell reprogramming process, limit iPS use in therapy and pose questions on the long-term behavior of these cells. In particular, despite the development of virus-free methods for their obtainment, a major and persisting drawback, is related to the acquisition of a stable pluripotent state, that is un-physiological and may lead to cell instability. The increased understanding of epigenetic mechanisms has paved the way to the use of "small molecules" and "epigenetic modifiers" that allow the fine tuning of cell genotype and phenotype. In particular, it was demonstrated that an adult mature cell could be directly converted into a different cell type with the use of these chemicals, obtaining a new patient-specific cell, suitable for cell therapy. This approach is simple and direct and may represent a very promising tool for the regenerative medicine of several and diverse degenerative diseases.

Indexed as

AnimalsCell- and Tissue-Based TherapyCell DifferentiationCellular ReprogrammingEpigenesis, GeneticHumansInduced Pluripotent Stem CellsCell conversionEpigenetic memoryRegenerative medicineReprogrammingTrans-differentiation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.